Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Benitec Biopharma Inc.BNTC · Entity 5596 | Chief Operating Officer | November 18, 2025 | November 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Benitec Biopharma Inc.
Report date November 18, 2025 · Filed November 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.53 · Expires 2035-11-18 | Direct | 500,000 |
Reported balance
After 2025-11-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-18 · Grant · Acquired 500,000 · Balance 500,000 F1: The stock options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2025 Filed Nov 20, 2025 17:37 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 500,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0001012975-25-000813 · form4.xml · derivative · entry 1 Mukadam Sophie · CIK 0002050122 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2035-11-18 F1 · derivative.exercise_date: The stock options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.